Boston expands digital offering with European launch of Heart Connect

2724
Boston Scientific’s Heart Connect system

Among the array of remote monitoring and digital arrhythmia management tools on display at the 2022 European Heart Rhythm Association annual meeting (EHRA 2022, 3‒5 April, Copenhagen, Denmark), Boston Scientific showcased its Heart Connect remote support system, which has recently launched in Europe.

Having gained CE mark in March 2022, Heart Connect is among the newest tools on a growing market for remote management and support in heart rhythm management, which has been jump-started by the pandemic.

Heart Connect—which is a part of the LATITUDE programming system—is aimed at offering real time support to clinicians using the Boston suite of arrhythmia management products, providing an instant link between the clinician and representatives from the company.

Using a battery-powered, remote console, a clinician can request and establish a connection with a Boston Scientific technical expert who can offer advice on device programming and complete device checks instantly. The platform uses Zoom communications software, so the participants can interact via a face-to-face video link with representatives in several geographies, and in a number of languages.

“With HeartConnect CE mark, we have a fantastic new product which enables us to provide premium service offerings to our customers. We know that post-COVID, virtual interactions will continue to be important to our customers, and with the Heart Connect system, the user can now share the programmer screen in real-time, to improve the interaction and the quality of service” says Angelo De Rosa, vice president & general manager, Rhythm Management EMEA at Boston Scientific.

Also at EHRA 2022, Boston Scientific marked its recent acquisition of Baylis Medical Company, a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures. Boston said that the acquisition would allow it to integrate the Baylis platforms with its existing electrophysiology and structural heart offerings.


LEAVE A REPLY

Please enter your comment!
Please enter your name here